Free Newsletter
GeoVax readies mid-stage AIDS vaccine trial
Atlanta-based GeoVax Labs is planning to launch a mid-stage study of its AIDS vaccine this fall. The Emory University spin-off says that the NIH study would recruit 225 volunteers to help test the safety and immunogenicity of their experimental vaccine.
The company has been developing a vaccine that it believes can significantly reduce the amount of drugs someone infected with HIV would have to take in order to control the viral load. CEO Robert McNally said that in animal studies the vaccine kept the viral load in check after six weeks of conventional therapy.
"You give these monkeys the virus, and they start developing the symptoms," McNally told the Atlanta Journal-Constitution. "Those given our vaccine, it slows down or reduces the viral load of the infection. This is significant because it is suppressing AIDS in monkeys. And that's what we are trying to do in people."
- read the report in the Atlanta Journal-Constitution
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
